303 related articles for article (PubMed ID: 17055069)
1. Novel modulators of poly(ADP-ribose) polymerase.
Szabo C; Pacher P; Swanson RA
Trends Pharmacol Sci; 2006 Dec; 27(12):626-30. PubMed ID: 17055069
[TBL] [Abstract][Full Text] [Related]
2. Caffeine metabolites are inhibitors of the nuclear enzyme poly(ADP-ribose)polymerase-1 at physiological concentrations.
Geraets L; Moonen HJ; Wouters EF; Bast A; Hageman GJ
Biochem Pharmacol; 2006 Sep; 72(7):902-10. PubMed ID: 16870158
[TBL] [Abstract][Full Text] [Related]
3. Poly (adp-ribose) polymerase inhibitors as potential therapeutic agents in stroke and neurotrauma.
Komjáti K; Besson VC; Szabó C
Curr Drug Targets CNS Neurol Disord; 2005 Apr; 4(2):179-94. PubMed ID: 15857303
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribose) polymerase inhibitors.
Southan GJ; Szabó C
Curr Med Chem; 2003 Feb; 10(4):321-40. PubMed ID: 12570705
[TBL] [Abstract][Full Text] [Related]
5. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.
Pacher P; Szabó C
Cardiovasc Drug Rev; 2007; 25(3):235-60. PubMed ID: 17919258
[TBL] [Abstract][Full Text] [Related]
6. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.
Virág L; Szabó C
Pharmacol Rev; 2002 Sep; 54(3):375-429. PubMed ID: 12223530
[TBL] [Abstract][Full Text] [Related]
7. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
[TBL] [Abstract][Full Text] [Related]
9. Poly (ADP-ribose) polymerase: An Overview of Mechanistic Approaches and Therapeutic Opportunities in the Management of Stroke.
Tiwari P; Khan H; Singh TG; Grewal AK
Neurochem Res; 2022 Jul; 47(7):1830-1852. PubMed ID: 35437712
[TBL] [Abstract][Full Text] [Related]
10. Poly(ADP-ribosyl)ation and stroke.
Chiarugi A
Pharmacol Res; 2005 Jul; 52(1):15-24. PubMed ID: 15911330
[TBL] [Abstract][Full Text] [Related]
11. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
[TBL] [Abstract][Full Text] [Related]
12. A key role for poly(ADP-ribose) polymerase-1 activity during human dendritic cell maturation.
Aldinucci A; Gerlini G; Fossati S; Cipriani G; Ballerini C; Biagioli T; Pimpinelli N; Borgognoni L; Massacesi L; Moroni F; Chiarugi A
J Immunol; 2007 Jul; 179(1):305-12. PubMed ID: 17579050
[TBL] [Abstract][Full Text] [Related]
13. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
Iwashita A; Tojo N; Matsuura S; Yamazaki S; Kamijo K; Ishida J; Yamamoto H; Hattori K; Matsuoka N; Mutoh S
J Pharmacol Exp Ther; 2004 Aug; 310(2):425-36. PubMed ID: 15075382
[TBL] [Abstract][Full Text] [Related]
14. Natural inhibitors of poly(ADP-ribose) polymerase-1.
Banasik M; Stedeford T; Strosznajder RP
Mol Neurobiol; 2012 Aug; 46(1):55-63. PubMed ID: 22476980
[TBL] [Abstract][Full Text] [Related]
15. Poly(ADP-ribose) polymerase-1 protects excessive DNA strand breaks from deterioration during repair in human cell extracts.
Parsons JL; Dianova II; Allinson SL; Dianov GL
FEBS J; 2005 Apr; 272(8):2012-21. PubMed ID: 15819892
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological inhibition of poly(ADP-ribose) polymerase in cardiovascular disorders: future directions.
Szabó C
Curr Vasc Pharmacol; 2005 Jul; 3(3):301-3. PubMed ID: 16026326
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications.
de la Lastra CA; Villegas I; Sánchez-Fidalgo S
Curr Pharm Des; 2007; 13(9):933-62. PubMed ID: 17430191
[TBL] [Abstract][Full Text] [Related]
18. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
Horvath EM; Szabó C
Drug News Perspect; 2007 Apr; 20(3):171-81. PubMed ID: 17520094
[TBL] [Abstract][Full Text] [Related]
19. Multiple roles for poly(ADP-ribose)polymerase-1 in neurological disease.
Kauppinen TM
Neurochem Int; 2007 Jun; 50(7-8):954-8. PubMed ID: 17222947
[TBL] [Abstract][Full Text] [Related]
20. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways.
Wang M; Wu W; Wu W; Rosidi B; Zhang L; Wang H; Iliakis G
Nucleic Acids Res; 2006; 34(21):6170-82. PubMed ID: 17088286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
